Synergy Pharmaceuticals Inc. (SGYP) Director John P. Brancaccio Sells 2,518 Shares
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Director John P. Brancaccio sold 2,518 shares of Synergy Pharmaceuticals stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $5.76, for a total transaction of $14,503.68. Following the completion of the transaction, the director now directly owns 21,883 shares in the company, valued at approximately $126,046.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) traded up 1.44% during trading on Wednesday, reaching $5.63. 5,645,202 shares of the company were exchanged. The company’s market capitalization is $1.01 billion. The firm’s 50 day moving average price is $4.96 and its 200 day moving average price is $3.84. Synergy Pharmaceuticals Inc. has a one year low of $2.50 and a one year high of $7.15.
Synergy Pharmaceuticals (NASDAQ:SGYP) last released its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by $0.03. Equities research analysts forecast that Synergy Pharmaceuticals Inc. will post ($1.03) earnings per share for the current fiscal year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/synergy-pharmaceuticals-inc-sgyp-director-john-p-brancaccio-sells-2518-shares.html
SGYP has been the topic of a number of research reports. BTIG Research initiated coverage on shares of Synergy Pharmaceuticals in a research report on Thursday, August 25th. They issued a “buy” rating and a $11.00 price objective on the stock. HC Wainwright set a $15.00 price objective on shares of Synergy Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, September 8th. Rodman & Renshaw reissued a “buy” rating and issued a $15.00 price objective on shares of Synergy Pharmaceuticals in a research report on Tuesday, July 12th. Roth Capital reissued a “buy” rating and issued a $6.50 price objective on shares of Synergy Pharmaceuticals in a research report on Thursday, May 26th. Finally, Zacks Investment Research lowered shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 24th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $9.75.
Hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. increased its stake in shares of Synergy Pharmaceuticals by 27.6% in the first quarter. JPMorgan Chase & Co. now owns 1,304,086 shares of the biopharmaceutical company’s stock valued at $3,600,000 after buying an additional 281,991 shares during the period. Landscape Capital Management L.L.C. increased its stake in shares of Synergy Pharmaceuticals by 1,693.9% in the first quarter. Landscape Capital Management L.L.C. now owns 1,000,000 shares of the biopharmaceutical company’s stock valued at $2,760,000 after buying an additional 944,254 shares during the period. Geode Capital Management LLC increased its stake in shares of Synergy Pharmaceuticals by 8.3% in the first quarter. Geode Capital Management LLC now owns 719,734 shares of the biopharmaceutical company’s stock valued at $1,986,000 after buying an additional 55,327 shares during the period. Nantahala Capital Management LLC bought a new stake in shares of Synergy Pharmaceuticals during the first quarter valued at approximately $828,000. Finally, Creative Planning increased its stake in shares of Synergy Pharmaceuticals by 1.3% in the second quarter. Creative Planning now owns 117,436 shares of the biopharmaceutical company’s stock valued at $446,000 after buying an additional 1,450 shares during the period. 56.67% of the stock is owned by institutional investors.
About Synergy Pharmaceuticals
Synergy Pharmaceuticals Inc (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease.
Receive News & Ratings for Synergy Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.